The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 411-420

  Jenneck, Claudia ^a   Novak, Natalija ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alefacept; Biologicals; Efficacy; Safety; Tolerability

Indexed keywords

ALEFACEPT; AZATHIOPRINE; CD2 ANTIGEN; CYCLOSPORIN; DITHRANOL; ETANERCEPT; FUMARIC ACID; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METHOTREXATE; PLACEBO; PSORALEN; RETINOID; STEROID; VITAMIN D DERIVATIVE;

ANTIGEN PRESENTING CELL; APOPTOSIS; BOLUS INJECTION; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON COLD; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; KIDNEY FAILURE; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MEMORY T LYMPHOCYTE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRURITUS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN ATROPHY; STRIA; T LYMPHOCYTE; TELANGIECTASIA; TERATOGENICITY; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 34547665618     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Biogen Idec Inc. 2005. Prescription information: Amevive (Alefacept). Cambridge, MA, U S A.
2. Christophers E. 2001. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol, 26:314-20.
3. Elder JT, Nair RP, Henseler T, et al. 2001. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol, 137:1447-54.
4. Ellis CN, Krueger GG. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med, 345:248-55.
5. Ellis CN, Mordin MM, Adler EY. 2003. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol, 4:131-9.
6. Feldman SR, Menter A, Koo JY. 2004. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol, 150:317-26.
7. Finlay AY, Khan GK. 1994. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp. Dermatol, 19:210-6.
8. Finlay AY, Salek MS, Haney J. 2003. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology, 206:307-15.
9. Goffe B, Papp K, Gratton D, et al. 2005. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther, 27:1912-21.
10. Gordon KB, Krueger GG, van de Kerkohf P, et al. 2005. Efficacy and safety of multiple courses of alefacept in combination with other psoriasis therapies. J Am Acad Dermatol, 52:183.
11. Gordon KB, Langley RG. 2003. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol, 2:624-8.
12. Gordon KB, Vaishnaw AK, O'Gorman et al. 2003. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T cell counts. Arch Dermatol, 139:1563-70.
13. Gottlieb AB, Boehncke WH, Darif M. 2005. Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol, 4:718-24.
14. + T cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol, 49:816-25.
15. Hodak E, David M. 2004. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther, 17:383-92.
16. Korman NJ, Moul DK. 2005. Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. Semin Culan Med Surg, 24:10-8.
17. Korver JE, van de Kerkhof PC, Pasch MC. 2006. Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? J Am Acad Dermatol, 54:742-3.
18. Kraan MC, van Kuijk AW, Dinant HJ, et al. 2002. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum, 46:2776-84.
19. Krell JM. 2006. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol, 54:1099-101.
20. Krueger G, Koo J, Lebwohl M, et al. 2001. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol, 137:280-4.
21. Krueger GG, Papp KA, Stough DB, et al. 2002. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad, Dermatol, 47:921-33.
22. Krueger JG. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 46:1-23.
23. Langley RG, Cherman AM, Gupta AK. 2005. Alefacept: an expert review concerning the treatment of psoriasis. Expert Opin Pharmacother, 6:2327-33.
24. Lebwohl M. 2003. Psoriasis. Lancet, 361:1197-204.
25. Lebwohl M, Christophers E, Langley R, et al. 2003. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol, 139:719-27.
26. Liu CM, McKenna JK, Krueger GG. 2004. Alefacept: a novel biologic in the treatment of psoriasis. Drugs Today, 40:961-74.
27. Lowe NJ, Gonzalez J, Bagel J, et al. 2003. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and eflicacy. Int J Dermatol, 42:224-30.
28. Luba KM, Stulberg DL. 2006. Chronic plaque psoriasis. Am Fam Physician, 73:636-44.
29. Majeau GR, Meier W, Jimmo B, et al. 1994. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol, 152:2753-67.
30. Menter A, Cather JC, Baker D, et al. 2006. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol, 54:61-3.
31. Miller GT, Hochman PS, Meier W, et al. 1993. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med, 178:211-22.
32. Myers W, Christiansen L, Gottlieb AB. 2005. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol, 53:S127-9.
33. Ortonne JP, Lebwohl M, Em Griffiths GC. 2003. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol, 13:117-23.
34. Papp KA. 2006. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res, 298:7-15.
35. Parrish CA, Sobera JO, Robbins CM, et al. 2006. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol, 5:339-40.
36. Robert C, Kupper TS. 1999. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med, 341:1817-28.
37. Sanders ME, Makgoba MW, Sharrow SO, et al. 1988. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol, 140:1401-7.
38. Scheinfeld N. 2005a. Alefacept: a safety profile. Expert Opin Drug Saf, 4:975-85.
39. Sweetser MT, Woodworth J, Swan S, et al. 2006. Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept. Dermatol Online J, 12:1.
40. Thaci D, Patzold S, Kaufmann R, et al. 2005. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol, 152:1048-50.
41. Vaishnaw AK, TenHoor CN. 2002. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn, 29:415-26.
42. van do Kerkhof P, Griffiths CE, Christophers E, et al. 2005. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology, 211:256-63.
43. Wong VK, Lebwohl M. 2003. The use of alefacept in the treatment of psoriasis. Skin Therapy Lett, 8:1-2, 7.
44. Yeung-Yue K, Aronson P, Murakawa G. 2005. Clinical improvment of palmoplantar pustular psoriasis with alefacept. Proceeding of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA, USA. J Am Acad Dermatol, 52:179.